News Releases

- Alpine Immune Sciences grants AbbVie option to license worldwide rights to ALPN-101,   a phase 2-ready,   first-in-class dual CD28/ICOS costimulation antagonist, building on AbbVie’s commitment to developing novel therapies in Immunology - Alpine Immune Sciences to receive $60 million in an

SEATTLE --(BUSINESS WIRE)--Jun. 15, 2020-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases,   today announced the company will present a poster at the AACR Virtual

-- ALPN-101 was well tolerated and exhibited potent pharmacodynamic activity, enabling Phase 2 development -- SEATTLE --(BUSINESS WIRE)--Jun. 8, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer

First presentation of Alpine’s Variant Tumor Necrosis Factor (TNF) Receptor Domain (vTD) Program demonstrating expanded applicability of its directed evolution platform SEATTLE --(BUSINESS WIRE)--Jun. 4, 2020-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy

SEATTLE --(BUSINESS WIRE)--May 29, 2020-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that the company will present two posters at the EULAR

SEATTLE --(BUSINESS WIRE)--May 26, 2020-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced its participation in an analyst-led fireside chat at the

- Granted FDA Orphan Drug Designations for ALPN-101 in Acute GVHD - - BALANCE and NEON-1 Trials Open for Enrollment - SEATTLE --(BUSINESS WIRE)--May 14, 2020-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for

- NEON-1 is now open for enrollment for patients with advanced malignancies - SEATTLE --(BUSINESS WIRE)--Apr. 27, 2020-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory

SEATTLE --(BUSINESS WIRE)--Apr. 20, 2020-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the AACR Virtual

Completion of Phase 1 Study for Lead Autoimmune/Inflammatory Disease Program, ALPN-101 BALANCE Trial of ALPN-101 in Acute GVHD Open for Enrollment NEON-1 Trial of ALPN-202 in Advanced Malignancies Open for Enrollment Orphan Drug Designations by the U.S.